Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,458 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis Clear all
Completed Not applicable Interventional

Amygdala Insula Retraining in the Management of Multiple Sclerosis Symptoms

NCT07427433
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Amygdala insula retraining, Lifestyle program
Behavioral
Lead sponsor
Chronic Conditions Research Fund
Other
Eligibility
21 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Decorah, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 8, 2026, 5:36 AM EDT
Recruiting Phase 4 Interventional

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

NCT06529406
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Las Vegas, Nevada • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 8, 2026, 5:36 AM EDT
Completed Phase 4 Interventional Results available

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

NCT03110315
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue, Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 8, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT01093326
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
16
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 8, 2026, 5:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program

NCT03954717
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Shepherd CAN DO Program
Behavioral
Lead sponsor
Shepherd Center, Atlanta GA
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 8, 2026, 5:36 AM EDT
Recruiting Not applicable Interventional

Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients

NCT07392879
View directory record Official record
Conditions
Progressive Multiple Sclerosis, Depression
Interventions
Virtual Reality, Standard care
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 8, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00053417
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 8, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream

NCT01853423
View directory record Official record
Conditions
Facial Angiofibroma
Interventions
Rapamune
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
3 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 8, 2026, 5:36 AM EDT
Completed No phase listed Observational

Pregnancy Exposure Registry for Tysabri®

NCT00472992
View directory record Official record
Conditions
Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 8, 2026, 5:36 AM EDT
Completed Phase 4 Interventional Results available

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

NCT01454791
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
diclofenac sodium topical gel, Placebo
Drug · Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 8, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia

NCT00376506
View directory record Official record
Conditions
Chronic Dysphagia, Multiple Sclerosis, Parkinson Disease
Interventions
Neurostimulation device for dysphagia, External vibrotactile device
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Sep 8, 2026, 5:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

NCT04448977
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrevus
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 8, 2026, 5:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

NCT06063850
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
AAV9-hSyn1-miGRIK2
Genetic
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 5:36 AM EDT
Terminated Phase 4 Interventional Results available

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

NCT03126760
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt ARD LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Palo Alto, California • Fort Collins, Colorado • Bradenton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 8, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 8, 2026, 5:36 AM EDT
Completed No phase listed Observational

Tuberous Sclerosis Complex Natural History Study: Renal Manifestations

NCT00598455
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 8, 2026, 5:36 AM EDT
Recruiting Not applicable Interventional

Blood Flow Restriction And Veterans With MS

NCT05433103
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Low-Load Exercise with Blood Flow Restriction, Low-Load Exercise Control Group
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 8, 2026, 5:36 AM EDT
Terminated No phase listed Observational

Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

NCT03926637
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Multiple Sclerosis Performance Test (MSPT)
Other
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
3,073 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
22
States / cities
Berkeley, California • Los Angeles, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 8, 2026, 5:36 AM EDT
Completed No phase listed Observational

PREG-MS: New England MS Pregnancy Registry

NCT03368157
View directory record Official record
Conditions
Multiple Sclerosis, Pregnancy Related
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Female only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 8, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

NCT00676156
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
oral lipoic acid (LA), lipoic acid (LA) with fish oil and LA without fish oil, R lipoic acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Sep 8, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis

NCT00110396
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon-beta-1a FBS-free/HSA-free
Biological
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 8, 2026, 5:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

NCT03109288
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 8, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

NCT01764737
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
VX15/2503, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Cullman, Alabama • Aurora, Colorado • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Sep 8, 2026, 5:36 AM EDT
Recruiting Not applicable Interventional

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

NCT06809192
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
4-session Relaxation Training, 4-session Behavioral Activation, 4-session Cognitive Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 8, 2026, 5:36 AM EDT